HeartWare HVAD Meets Primary Endpoint For Destination Therapy
This article was originally published in The Gray Sheet
Executive Summary
Results of the 446-patient trial presented at the International Society for Heart and Lung Transplantation Annual Meeting show non-inferiority of the HVAD to FDA-approved ventricular assist devices in destination therapy patients.